Skip to main content

Table 1 Targeted therapies in clinical development

From: The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Target Agent Agent class
EGFR IMC-C225 Cetuximab, Erbitux (Imclone) Monoclonal antibody
  ABX-EGF (Abgenix) Monoclonal antibody
  EMD 72000 (Merck KgaA Darmstadt) Monoclonal antibody
  ZD 1839 gefitinib, Iressa (AstraZeneca) Small molecule kinase inhibitor
  OSI-774, erlotinib, Tarceva(OSI-Pharmaceuticals) Small molecule kinase inhibitor
  CI-1033/PD183805 (Pfizer) Small molecule kinase inhibitor
  EKB-569 (Wyeth Ayerst) Small molecule kinase inhibitor
  GW2016/572016(GlaxoSmithKline) Small molecule kinase inhibitor
HER2/neu Trastuzumab, Herceptin(Genentech) Monoclonal antibody
  2C4 (Genentech) Monoclonal antibody
  17-AAG Geldanamycin derivative inhibits HSP90
  TAK-165(Takeda Pharmaceuticals) Small molecule inhibitor
  GW2016/572016(GlaxoSmithKline) Small molecule kinase inhibitor
  CP 724, 714 (Pfizer) Small molecule inhibitor
Ras R115777(Johnson and Johnson) Farnesyl transferase inhibitor
  SCH66336 (Schering-Plough) Farnesyl transferase inhibitor
  BMS214662(Bristol Myers Squibb) Farnesyl transferase inhibitor
  CT-2584HMS (Cell Therapeutics) Farnesyl transferase inhibitor
Raf BAY 43-9006 (Onyx/Bayer) Small molecule kinase inhibitor
MEK PD 184352/CI-1040 (Pfizer) Small molecule kinase inhibitor
PKC-α ISIS 3521/LY900003 Affinitak(ISIS Pharmaceuticals) Antisense oligonucleotide
  CGP41251/PKC412 (Novartis) Staurosporine analogue
  Bryostatin-1 Small molecule kinase inhibitor
  UCN-01 (Kyowa Hakko Kogyo) Staurosporine analogue
PKC-β LY333531 (Eli Lilly) Small molecule kinase inhibitor
Akt 17-AAG Inhibitor of HSP90
  Perifosine (Zenataris) Alkylphospholipid
mTOR CCI-779 (Wyeth) Inhibits mTOR kinase by binding to FKBP
  RAD001 (Novartis) Inhibits mTOR kinase by binding to FKBP
  1. EGFR, epidermal growth factor receptor; MEK, MAP kinase/ERK kinase; mTOR, mammalian target of rapamycin; PKC, protein kinase C.
\